Market Overview:
The global retinitis pigmentosa treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to factors such as the increasing prevalence of retinitis pigmentosa, technological advancements in the field of ophthalmology, and rising awareness about retinitis pigmentosa treatments. The global retinitis pigmentosa treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into BNP-RP (benzofuran naphthoquinone), cenegermin (bimatoprost 0.03%), CPK-850 (ciprofloxacin hydrochloride 500 mg), cutamesine (amino acid derivative), FAB-111 (fumarylacetoacetate hydrolase inhibitor), and others. On the basis of application, the market is segmented into hospital care, clinic care, and homecare. The regional segments are North America, Latin America Europe Asia Pacific Middle East & Africa).
Product Definition:
Retinitis pigmentosa (RP) is a group of inherited diseases that damage the retina, the light-sensitive tissue at the back of the eye. RP can lead to blindness. There is no cure for RP, but treatments are available to help people with RP maintain their vision as long as possible.
BNP-RP:
BNP-RP is short for Bovine Neurotrophic Protein and Recombinant Proteins, it's a type of growth factor that helps the retinal pigment epithelium (RPE) to grow & repair damaged RPE cells. It also helps in increasing the permeability of blood-retina barrier by down regulating MMP-2 & -9 levels.
Cenegermin:
Cenegermin (Ranibizumab) is a type of interleukin inhibitor. Interleukins are cytokines that are produced in response to injury or inflammation and play an important role in the pathogenesis of retinitis pigmentosa (RP). Cenegermin works by decreasing the production of cytokines which results in reduced inflammation and improved vision.
Application Insights:
Based on application, the market is segmented into hospital, clinic and homecare. The hospital segment dominated the market in 2017 due to a large patient base with retinitis pigmentosa. Retinitis pigmentosa is a rare disease that mainly affects older people; thus most of the hospitals have started offering treatment for this condition which has resulted in high demand for these drugs at hospitals.
The homecare segment is expected to grow at fastest rate during forecast period owing to increasing awareness about availability of treatments for RP other than medical prescription drugs which are expensive and not covered by insurance companies. Moreover, growing prevalence of retinitis pigmentosa coupled with rising number of patients seeking treatment outside medical settings will boost growth over the forecast period.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of players, high adoption rate for new therapies, and favorable reimbursement policies are some factors contributing to its growth. Moreover, the growing geriatric population is expected to drive regional growth over the forecast period.
Asia Pacific is expected to grow at a lucrative CAGR during the forecast period owing to increasing disposable income and awareness about available treatment options coupled with rising healthcare expenditure in emerging countries such as China and India. Furthermore, an increase in cases due to UV exposure has led Retinitis Pigmentosa International (RPi), an organization that raises funds for research activities related retinitis pigmentosa worldwide.
Growth Factors:
- Increasing prevalence of Retinitis Pigmentosa (RP) is expected to drive the growth of Retinitis Pigmentosa Treatment market.
- Rising awareness about Retinitis Pigmentosa and its treatment options is anticipated to boost the demand for Retinitis Pigmentosa Treatment products over the forecast period.
- Technological advancements in RP treatment therapies are likely to propel the growth of this market in near future.
- Growing number of clinical studies on new RP treatments is projected to create lucrative opportunities for players operating in this market during forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Retinitis Pigmentosa Treatment Market Research Report
By Type
BNP-RP, Cenegermin, CPK-850, Cutamesine, FAB-111, Others
By Application
Hospital, Clinic, Homecare
By Companies
Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., M's Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
205
Number of Tables & Figures
144
Customization Available
Yes, the report can be customized as per your need.
Global Retinitis Pigmentosa Treatment Market Report Segments:
The global Retinitis Pigmentosa Treatment market is segmented on the basis of:
Types
BNP-RP, Cenegermin, CPK-850, Cutamesine, FAB-111, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Homecare
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Astellas Pharma Inc.
- Caladrius Biosciences, Inc.
- Dompe Farmaceutici S.p.A.
- Genable Technologies Limited
- Genethon
- GenSight Biologics S.A.
- Grupo Ferrer Internacional, S.A.
- ID Pharma Co., Ltd.
- InFlectis BioScience
- International Stem Cell Corporation
- Ionis Pharmaceuticals, Inc.
- M's Science Corporation
- Mimetogen Pharmaceuticals Inc.
- Nanovector s.r.l.
- Orphagen Pharmaceuticals, Inc.
Highlights of The Retinitis Pigmentosa Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- BNP-RP
- Cenegermin
- CPK-850
- Cutamesine
- FAB-111
- Others
- By Application:
- Hospital
- Clinic
- Homecare
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Retinitis Pigmentosa Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no cure for Retinitis Pigmentosa, but there are treatments that can help improve the symptoms. Treatment options may include medications, surgery, and light therapy.
Some of the major players in the retinitis pigmentosa treatment market are Astellas Pharma Inc., Caladrius Biosciences, Inc., Dompe Farmaceutici S.p.A., Genable Technologies Limited, Genethon, GenSight Biologics S.A., Grupo Ferrer Internacional, S.A., ID Pharma Co., Ltd., InFlectis BioScience, International Stem Cell Corporation, Ionis Pharmaceuticals, Inc., M's Science Corporation, Mimetogen Pharmaceuticals Inc., Nanovector s.r.l., Orphagen Pharmaceuticals, Inc..
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Retinitis Pigmentosa Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Retinitis Pigmentosa Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Retinitis Pigmentosa Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Retinitis Pigmentosa Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Retinitis Pigmentosa Treatment Market Size & Forecast, 2020-2028
4.5.1 Retinitis Pigmentosa Treatment Market Size and Y-o-Y Growth
4.5.2 Retinitis Pigmentosa Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 BNP-RP
5.2.2 Cenegermin
5.2.3 CPK-850
5.2.4 Cutamesine
5.2.5 FAB-111
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.2.3 Homecare
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Retinitis Pigmentosa Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Retinitis Pigmentosa Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 BNP-RP
9.6.2 Cenegermin
9.6.3 CPK-850
9.6.4 Cutamesine
9.6.5 FAB-111
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.10.3 Homecare
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 BNP-RP
10.6.2 Cenegermin
10.6.3 CPK-850
10.6.4 Cutamesine
10.6.5 FAB-111
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.10.3 Homecare
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 BNP-RP
11.6.2 Cenegermin
11.6.3 CPK-850
11.6.4 Cutamesine
11.6.5 FAB-111
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.10.3 Homecare
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 BNP-RP
12.6.2 Cenegermin
12.6.3 CPK-850
12.6.4 Cutamesine
12.6.5 FAB-111
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.10.3 Homecare
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 BNP-RP
13.6.2 Cenegermin
13.6.3 CPK-850
13.6.4 Cutamesine
13.6.5 FAB-111
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.10.3 Homecare
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Retinitis Pigmentosa Treatment Market: Competitive Dashboard
14.2 Global Retinitis Pigmentosa Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Astellas Pharma Inc.
14.3.2 Caladrius Biosciences, Inc.
14.3.3 Dompe Farmaceutici S.p.A.
14.3.4 Genable Technologies Limited
14.3.5 Genethon
14.3.6 GenSight Biologics S.A.
14.3.7 Grupo Ferrer Internacional, S.A.
14.3.8 ID Pharma Co., Ltd.
14.3.9 InFlectis BioScience
14.3.10 International Stem Cell Corporation
14.3.11 Ionis Pharmaceuticals, Inc.
14.3.12 M's Science Corporation
14.3.13 Mimetogen Pharmaceuticals Inc.
14.3.14 Nanovector s.r.l.
14.3.15 Orphagen Pharmaceuticals, Inc.
